Effect of desipramine on patients with breathing disorders in RETT syndrome

Rett Syndrome (RTT) is a severe neurodevelopmental condition with breathing disorders, affecting around one in 10,000 female births. Desipramine, a noradrenaline reuptake inhibitor, reduced the number of apneas in Mecp2‐deficient mice, a model of RTT. We planned a phase 2 trial to test its efficacy and its safety on breathing patterns in 36 girls with RTT.

[1]  A. Bird,et al.  Rett Syndrome: Crossing the Threshold to Clinical Translation , 2016, Trends in Neurosciences.

[2]  H. Kerstjens,et al.  Validity and Predictive Value of a Portable Two-Channel Sleep-Screening Tool in the Identification of Sleep Apnea in Patients With Heart Failure. , 2015, Journal of cardiac failure.

[3]  S. Pati,et al.  Rett Syndrome: Reaching for Clinical Trials , 2015, Neurotherapeutics.

[4]  X. Castells,et al.  Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents. , 2014, The Cochrane database of systematic reviews.

[5]  J. Ramirez,et al.  Breathing challenges in Rett Syndrome: Lessons learned from humans and animal models , 2013, Respiratory Physiology & Neurobiology.

[6]  J J Swen,et al.  Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants , 2013, Clinical pharmacology and therapeutics.

[7]  A. de Weerd,et al.  Respiratory and sleep disorders in female children with atypical Rett syndrome caused by mutations in the CDKL5 gene , 2013, Developmental medicine and child neurology.

[8]  Rodney C. Samaco,et al.  Preclinical research in Rett syndrome: setting the foundation for translational success , 2012, Disease Models & Mechanisms.

[9]  W. Kaufmann,et al.  Rett syndrome: Revised diagnostic criteria and nomenclature , 2010, Annals of neurology.

[10]  J. Ramirez,et al.  Respiratory Physiology & Neurobiology Breathing Disorders in Rett Syndrome: Progressive Neurochemical Dysfunction in the Respiratory Network after Birth , 2022 .

[11]  S. Hansen,et al.  Cardiorespiratory challenges in Rett's syndrome , 2008, The Lancet.

[12]  H. Zoghbi,et al.  Specific mutations in Methyl-CpG-Binding Protein 2 confer different severity in Rett syndrome , 2008, Neurology.

[13]  S. Zanella,et al.  Oral treatment with desipramine improves breathing and life span in Rett syndrome mouse model , 2008, Respiratory Physiology & Neurobiology.

[14]  D. Einhorn,et al.  Validation of the ApneaLink for the screening of sleep apnea: a novel and simple single-channel recording device. , 2007, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

[15]  J. Roux,et al.  Treatment with desipramine improves breathing and survival in a mouse model for Rett syndrome , 2007, The European journal of neuroscience.

[16]  D. Richter,et al.  Breathing dysfunctions associated with impaired control of postinspiratory activity in Mecp2−/y knockout mice , 2007, The Journal of physiology.

[17]  Debra E Weese-Mayer,et al.  Autonomic Nervous System Dysregulation: Breathing and Heart Rate Perturbation During Wakefulness in Young Girls with Rett Syndrome , 2006, Pediatric Research.

[18]  Laurent Villard,et al.  Mecp2 Deficiency Disrupts Norepinephrine and Respiratory Systems in Mice , 2005, The Journal of Neuroscience.

[19]  J. Christodoulou,et al.  Medium-term open label trial of L-carnitine in Rett syndrome , 2001, Brain and Development.

[20]  G. Jamal,et al.  Characterisation of breathing and associated central autonomic dysfunction in the Rett disorder , 2001, Archives of disease in childhood.

[21]  T. Diperri,et al.  Progressive Cardiac Dysautonomia Observed in Patients Affected by Classic Rett Syndrome and Not in the Preserved Speech Variant , 2001, Journal of child neurology.

[22]  H. Zoghbi,et al.  Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2 , 1999, Nature Genetics.

[23]  D. Atkins,et al.  AHA Scientific Statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.

[24]  A. Kerr.  A review of the respiratory disorder in the Rett syndrome. , 1992, Brain & development.

[25]  H. Zoghbi,et al.  Cerebrospinal fluid biogenic amines and biopterin in rett syndrome , 1989, Annals of neurology.

[26]  A. Domínguez-Gil,et al.  Monitoring of Serum Levels of Imipramine and Desipramine and Individualization of Dose in Enuretic Children , 1984, Therapeutic drug monitoring.

[27]  I. Narang,et al.  The utility of a portable sleep monitor to diagnose sleep-disordered breathing in a pediatric population. , 2014, Canadian respiratory journal.

[28]  Rodney C. Samaco,et al.  Female Mecp2(+/-) mice display robust behavioral deficits on two different genetic backgrounds providing a framework for pre-clinical studies. , 2013, Human molecular genetics.

[29]  J. Roux,et al.  Biogenic Amines in Rett Syndrome: The Usual Suspects , 2010, Behavior genetics.

[30]  R. Prescott,et al.  Rett syndrome: analysis of deaths in the British survey. , 1997, European child & adolescent psychiatry.